Koji Ohsumi

USPTO Granted Patents = 22 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 6.4

ph-index = 5

Forward Citations = 169(Granted Patents)

Location History:

Tokyo, JP (1994)
Kanagawa, JP (2013)
Kawasaki, JP (1993 - 2018)

Company Filing History:

Japanese Foundation for Cancer Research

where one patent can have more than one assignee

Years Active: 1993-2018

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9907766 - Sweetness receptor antagonist (2018-03-06),

2. 9655879 - Heteroarylcarboxylic acid ester derivative (2017-05-23),

3. 9346821 - Heterocyclic carboxylic acid ester derivative (2016-05-24),

4. 9227949 - Heteroarylcarboxylic acid ester derivative (2016-01-05),

5. 9115107 - Heteroarylcarboxylic acid ester derivative (2015-08-25),

6. 9024044 - Heteroarylcarboxylic acid ester derivative (2015-05-05),

7. 8877805 - Heteroarylcarboxylic acid ester derivative (2014-11-04),

8. 8609715 - Heteroarylcarboxylic acid ester derivative (2013-12-17),

9. 7956041 - Prophylactic and therapeutic agent of diabetes mellitus (2011-06-07),

10. 7834006 - Fused polycyclic compounds (2010-11-16),

11. 7645787 - Pyrazole derivatives and diabetic medicine containing them (2010-01-12),

12. 7517996 - Azole compound (2009-04-14),

13. 7256209 - Pyrazole derivatives and diabetic medicine containing them (2007-08-14),

14. 7247616 - Pyrazole derivatives and diabetic medicine containing them (2007-07-24),

15. 7015201 - Pyrazole derivatives and diabetic medicine containing them (2006-03-21),

Title: Innovations of Koji Ohsumi: A Pioneer in Diabetes Research

Introduction

Koji Ohsumi, based in Kawasaki, Japan, is a prolific inventor known for his significant contributions to medical science, particularly in the domain of diabetes and metabolic disorders. With a remarkable portfolio of 22 patented innovations, Ohsumi has emerged as a key figure in developing therapeutic compounds aimed at combating serious health issues.

Latest Patents

Among his latest patents, Ohsumi has developed a "Sweetness receptor antagonist." This invention comprises a composition represented by a specific formula, which is valuable for the prevention and treatment of metabolic syndrome, diabetes, obesity, and related conditions. In addition to this, he has introduced a "Heteroarylcarboxylic acid ester derivative." This compound, also articulated by a defined formula, serves as a hyperglycemic inhibitor with serine protease inhibitory action, functioning effectively as a preventative or therapeutic medication for diabetes.

Career Highlights

Koji Ohsumi has made significant strides throughout his career, particularly during his tenure at major organizations, including Ajinomoto Co., Ltd. and the Japanese Foundation for Cancer Research. His innovative work in these prominent institutions has facilitated advances in the understanding and management of diabetes and associated metabolic disorders.

Collaborations

Ohsumi's journey has also seen fruitful collaborations with esteemed colleagues, notably Toshihiro Hatanaka and Hiroyuki Matsueda. These partnerships have allowed for the exchange of ideas and techniques, driving forward the research and development of new, effective therapeutic solutions.

Conclusion

Koji Ohsumi's contributions to the field of medical science, particularly through his innovative patents, mark a remarkable legacy in the ongoing battle against diabetes and metabolic syndrome. His dedication to advancing therapeutic knowledge continues to inspire future generations of researchers and inventors in the health sciences.

This text is generated by artificial intelligence and may not be accurate.